Targeting multiple signal transduction pathways in lung cancer
- PMID: 16159418
- DOI: 10.3816/clc.2005.s.006
Targeting multiple signal transduction pathways in lung cancer
Abstract
Growth factor signals are propagated from the cell surface to intracellular processes that control critical functions such as growth, differentiation, angiogenesis, and inhibition of apoptosis via sequential kinase signaling. These kinases are receptor kinases, which are transmembrane proteins such as epidermal growth factor receptor or cytoplasmic kinases such as Src kinase. In malignancies, these signaling pathways are often exploited to optimize tumor growth and metastasis. Thus, they represent attractive targets for cancer therapy. This review will summarize current knowledge of the small-molecule multiple-kinase inhibitors in lung cancer therapy. These inhibitors generally hinder the phosphorylation of several protein kinases of membrane receptors, such as vascular endothelial growth factor receptors, platelet-derived growth factor receptors, the human epidermal growth factor receptor family, and cytoplasmic receptors such as c-Kit, Raf kinase, and FLT3. These inhibitors include ZD6474, SU11248, AEE 788, sorafenib, vatalanib, and AG-013736.
Similar articles
-
Key cancer cell signal transduction pathways as therapeutic targets.Eur J Cancer. 2006 Feb;42(3):290-4. doi: 10.1016/j.ejca.2005.07.034. Epub 2006 Jan 11. Eur J Cancer. 2006. PMID: 16376541 Review.
-
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.Semin Oncol. 2006 Aug;33(4):392-406. doi: 10.1053/j.seminoncol.2006.04.002. Semin Oncol. 2006. PMID: 16890795 Review.
-
Cell signalling: growth factors and tyrosine kinase receptors.Clin Transl Oncol. 2006 Feb;8(2):77-82. doi: 10.1007/s12094-006-0162-1. Clin Transl Oncol. 2006. PMID: 16632420 Review.
-
Combined targeted therapies in non-small cell lung cancer: a winner strategy?Curr Opin Oncol. 2007 Mar;19(2):98-102. doi: 10.1097/CCO.0b013e328011beec. Curr Opin Oncol. 2007. PMID: 17272980 Review.
-
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.Clin Lung Cancer. 2005 Sep;7 Suppl 1:S31-8. doi: 10.3816/clc.2005.s.005. Clin Lung Cancer. 2005. PMID: 16159417 Review.
Cited by
-
Induction of BCL2-Interacting Killer, BIK, is Mediated for Anti-Cancer Activity of Curcumin in Human Head and Neck Squamous Cell Carcinoma Cells.J Cancer. 2015 Feb 12;6(4):327-32. doi: 10.7150/jca.11185. eCollection 2015. J Cancer. 2015. PMID: 25767602 Free PMC article.
-
Salivary analysis of oral cancer biomarkers.Br J Cancer. 2009 Oct 6;101(7):1194-8. doi: 10.1038/sj.bjc.6605290. Br J Cancer. 2009. PMID: 19789535 Free PMC article.
-
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.Lung Cancer. 2011 Feb;71(2):151-5. doi: 10.1016/j.lungcan.2010.05.022. Epub 2010 Jul 1. Lung Cancer. 2011. PMID: 20580118 Free PMC article. Clinical Trial.
-
General aspects of colorectal cancer.ISRN Oncol. 2012;2012:139268. doi: 10.5402/2012/139268. Epub 2012 Nov 14. ISRN Oncol. 2012. PMID: 23209942 Free PMC article.
-
Pleural fluid analysis of lung cancer vs benign inflammatory disease patients.Br J Cancer. 2010 Mar 30;102(7):1180-4. doi: 10.1038/sj.bjc.6605607. Epub 2010 Mar 9. Br J Cancer. 2010. PMID: 20216542 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous